Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1559-1568

  Xun, Yun Hao ^a,b   Shi, Jun Ping ^a   Li, Chun Qing ^a   Li, Dan ^b   Shi, Wei Zhen ^a   Pan, Qing Chun ^b   Guo, Jian Chun ^a   Zang, Guo Qing ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acute on chronic liver failure; Hepatitis B; Models for end stage liver disease; Prognosis; score

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIBIOTIC AGENT; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LACTULOSE; LAMIVUDINE; PROTON PUMP INHIBITOR; SODIUM;

ACUTE ON CHRONIC HEPATITIS B LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; DISEASE MODEL; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; LIVER SUPPORT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MONOTHERAPY; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SODIUM BLOOD LEVEL; SURVIVAL; SURVIVAL TIME; VIRUS RESISTANCE;

ADULT; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; HEPATITIS B; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84899563832     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1983     Document Type: Article

References (31)

1. Sarin SK, Kumar A, Almeida JA, et al: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 3:269-282, 2009.
2. Wong VW and Chan HL: Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol 24: 1179-1186, 2009.
3. Kamath PS and Kim WR; Advanced Liver Disease Study Group: The model for end-stage liver disease (MELD). Hepatology 45:797-805, 2007. (Pubitemid 46450631)
4. Gitto S, Lorenzini S, Biselli M, Conti F, Andreone P and Bernardi M: Allocation priority in non-urgent liver transplantation: an overview of proposed scoring systems. Dig Liver Dis 41: 700-706, 2009.
5. Sun LJ, Yu JW, Zhao YH, Kang P and Li SC: Influential factors of prognosis in lamivudine treatment for patients with acute-onchronic hepatitis B liver failure. J Gastroenterol Hepatol 25: 583-590, 2010.
6. Sun QF, Ding JG, Xu DZ, et al: Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 16: 464-470, 2009.
7. Yu JW, Sun LJ, Zhao YH and Li SC: Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 23: 1242-1249, 2008.
8. Lee WC, Chou HS, Wu TJ, Lee CS, Lee CF and Chan KM: Indicators and outcome of liver transplantation in acute liver decompensation after flares of hepatitis B. J Viral Hepat 18: 193-199, 2011.
9. Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ and Chen YP: A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol 9: 351-356, 2011.
10. Cai CJ, Chen HA, Lu MQ and Chen GH: Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B. Chin Med J (Engl) 121: 2065-2069, 2008.
11. Lee WM, Squires RH Jr, Nyberg SL, Doo E and Hoofnagle JH: Acute liver failure: summary of a workshop. Hepatology 47: 1401-1415, 2008. (Pubitemid 351547926)
12. Novelli G, Rossi M, Ferretti G, Pugliese F, Travaglia D, Guidi S, Novelli S, Lai Q, Morabito V and Berloco PB: Predictive parameters after molecular absorbent recirculating system treatment integrated with model for end stage liver disease model in patients with acute-on-chronic liver failure. Transplant Proc 42: 1182-1187, 2010.
13. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC and Kumar A: Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53: 774-780, 2011.
14. Liu Q, Liu Z, Wang T, Wang Q, Shi X and Dao W: Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval. J Gastroenterol Hepatol 22: 2101-2106, 2007. (Pubitemid 350145590)
15. Liu XY, Hu JH, Wang HF and Chen JM: Etiological analysis of 1977 patients with acute liver failure, subacute liver failure and acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi 16: 772-775, 2008 (In Chinese).
16. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER and Kim WR: A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464-470, 2001. (Pubitemid 32119037)
17. Sharma P, Schaubel DE, Sima CS, Merion RM and Lok AS: Re-weighting the model for end-stage liver disease score components. Gastroenterology 135: 1575-1581, 2008.
18. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B and Bosch J: An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 13: 1174-1180, 2007. (Pubitemid 47307228)
19. Heuman DM, Mihas AA, Habib A, Gilles HS, Stravitz RT, Sanyal AJ and Fisher RA: MELD-XI: a rational approach to 'sickest first' liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 13: 30-37, 2007. (Pubitemid 46099971)
20. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E and Therneau TM: Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359: 1018-1026, 2008.
21. Neuberger J, Gimson A, Davies M, Akyol M, O'Grady J, Burroughs A and Hudson M; Liver Advisory Group; UK Blood and Transplant: Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 57: 252-257, 2008. (Pubitemid 351158055)
22. Bewick V, Cheek L and Ball J: Statistics review 13: receiver operating characteristic curves. Crit Care 8: 508-512, 2004. (Pubitemid 40073688)
23. DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845, 1988.
24. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP and Terrault NA: Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 41: 32-39, 2005. (Pubitemid 40066380)
25. Huo SC, Huo TI, Lin HC, Chi CW, Lee PC, Tseng FW and Lee SD: Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation 84: 1406-1412, 2007. (Pubitemid 350294715)
26. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B and Held PJ: Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 9: 12-18, 2003. (Pubitemid 36104909)
27. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY and Lee SD: Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 42: 826-832, 2005.
28. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association: Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi 14: 643-646, 2006 (In Chinese).
29. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, Sung JJ and Chan HL: Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 54: 236-242, 2011.
30. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S and Sarrazin C: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50: 2001-2006, 2009.
31. Christensen E: Prognostic models including the Child-Pugh, MELD and Mayo risk scores-where are we and where should we go? J Hepatol 41: 344-350, 2004.